Juliana C N Chan1, Pongamorn Bunnag2, Siew P Chan3, Iris T I Tan4, Shih-Tzer Tsai5, Ling Gao6, Wolfgang Landgraf7. 1. Department of Medicine and Therapeutics, Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong. Electronic address: jchan@cuhk.edu.hk. 2. Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3. University of Malaya Medical Centre, Kuala Lumpur, Malaysia. 4. University of The Philippines, Manila, Philippines. 5. Cheng Hsin General Hospital, Taipei, Taiwan. 6. Analysta Inc., Somerset, NJ, USA. 7. Sanofi, Frankfurt, Germany.
Abstract
AIMS: To compare outcomes between Asian and non-Asian patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin glargine 100 units (U)/mL (Gla-100) in randomised controlled clinical trials. METHODS: Post hoc analysis of patient-level data (Asian n = 235; non-Asian n = 3351) from 16 trials. RESULTS: At baseline, Asian patients were younger with lower body mass index (BMI), fasting C-peptide, and fasting plasma glucose (FPG) than non-Asian patients (all P < .001). Asian patients had a higher mean glycosylated haemoglobin (HbA1c) at Week 24 and less reduction in HbA1c from baseline (7.4% vs. 7.2%; -1.3% vs. -1.6%, respectively; P = .0001), and were less likely to achieve HbA1c <7.0% (40% vs. 47%; P = .002) than non-Asian patients. Reductions in FPG and rates of hypoglycaemia were similar between Asian and non-Asian patients. Asian patients had less weight gain than non-Asian patients (+1.3 vs. +1.9 kg, respectively, P = .013). CONCLUSIONS: In our post hoc meta-analysis, Gla-100 effectively lowers HbA1c and FPG in Asian patients with T2D uncontrolled on OADs with similar incidence of hypoglycaemia and less absolute weight gain compared with non-Asian patients. At a similar FPG reduction, fewer Asian patients achieved HbA1c target <7.0%, suggesting that prandial glucose needs to be addressed.
RCT Entities:
AIMS: To compare outcomes between Asian and non-Asian patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin glargine 100 units (U)/mL (Gla-100) in randomised controlled clinical trials. METHODS: Post hoc analysis of patient-level data (Asian n = 235; non-Asian n = 3351) from 16 trials. RESULTS: At baseline, Asian patients were younger with lower body mass index (BMI), fasting C-peptide, and fasting plasma glucose (FPG) than non-Asian patients (all P < .001). Asian patients had a higher mean glycosylated haemoglobin (HbA1c) at Week 24 and less reduction in HbA1c from baseline (7.4% vs. 7.2%; -1.3% vs. -1.6%, respectively; P = .0001), and were less likely to achieve HbA1c <7.0% (40% vs. 47%; P = .002) than non-Asian patients. Reductions in FPG and rates of hypoglycaemia were similar between Asian and non-Asian patients. Asian patients had less weight gain than non-Asian patients (+1.3 vs. +1.9 kg, respectively, P = .013). CONCLUSIONS: In our post hoc meta-analysis, Gla-100 effectively lowers HbA1c and FPG in Asian patients with T2D uncontrolled on OADs with similar incidence of hypoglycaemia and less absolute weight gain compared with non-Asian patients. At a similar FPG reduction, fewer Asian patients achieved HbA1c target <7.0%, suggesting that prandial glucose needs to be addressed.
Authors: James Ling; Emily W M Poon; Aimin Yang; Theresa Yeung; Kitman Loo; Risa Ozaki; Ronald C W Ma; Andrea O Y Luk; Alice P S Kong; Juliana C N Chan; Elaine Chow Journal: Diabetes Ther Date: 2021-03-18 Impact factor: 2.945
Authors: Robyn K Pollom; Liza L Ilag; Lyndon B Lacaya; Tina M Morwick; Ramón Ortiz Carrasquillo Journal: Diabetes Ther Date: 2019-01-02 Impact factor: 2.945
Authors: Alice P S Kong; Thomas Lew; Eric S H Lau; Lee-Ling Lim; Jothydev Kesavadev; Weiping Jia; Wayne H-H Sheu; Leorino Sobrepena; Alexander T B Tan; Thy Khue Nguyen; Kun-Ho Yoon; Ke Wang; Kamlanathan Kodiappan; Tamás Treuer; Juliana C N Chan Journal: Diabetes Obes Metab Date: 2020-02-03 Impact factor: 6.577